ReviewJournal of molecular neuroscience : MN2026

Reimagining GSK-3β Therapeutics in Alzheimer's Disease: From Inhibition to Activity Normalization and Targeted Degradation.

Emad Manni et al.PubMed ↗Publisher ↗

No numbers read from the abstract.